Intuitive Surgical: A Market Leader for the Future.

Intuitive Surgical is the global leader in robotic-assisted surgery and one of the most important companies in modern healthcare technology. Best known for its da Vinci surgical systems and growing Ion platform, the company combines strong innovation with a business model built on recurring revenue from instruments, accessories, and service contracts. With a growing number of systems installed in hospitals around the world, expanding use across more types of procedures, and long term tailwinds from the shift toward minimally invasive surgery, Intuitive Surgical appears well positioned for continued growth. The question remains: Does this healthcare leader deserve a spot in your portfolio?

This is not a financial advice. I am not a financial advisor and I only do these post in order to do my own analysis and elaborate about my decisions, especially for my copiers and followers. If you consider investing in any of the ideas I present, you should do your own research or contact a professional financial advisor, as all investing comes with a risk of losing money. You are also more than welcome to copy me. 

For full disclosure, I should mention that I do not own any shares in Intuitive Surgical at the time of writing this analysis. If you would like to copy or view my portfolio, you can find instructions on how to do so here. If you want to purchase shares or fractional shares of Intuitive Surgical, you can do so through eToro. eToro is a highly user-friendly platform that allows you to get started on investing with as little as $50.

The Business

Intuitive Surgical was founded in 1995 in California and has grown into the global leader in robotic-assisted minimally invasive surgery. The company built its business around the da Vinci Surgical System, which allows surgeons to perform complex procedures through small incisions with greater precision, better visibility, and improved control while sitting comfortably at an ergonomic console. The system is not designed to replace the surgeon but to help the surgeon operate with more accuracy and less fatigue during long procedures. Over the years, Intuitive Surgical has expanded beyond surgery with the launch of the Ion Endoluminal System, which is used for minimally invasive lung biopsies and gives the company exposure to the diagnostic side of healthcare as well. Its business model is highly attractive and follows a razor-and-blade structure, where hospitals buy or lease the systems and then continue to purchase instruments, accessories, and service contracts every time a procedure is performed. This creates a large and highly predictable stream of recurring revenue that grows as procedure volumes increase. More than 20 million patients globally have now been treated using its platforms, which highlights both the scale of the business and the trust healthcare providers place in its technology. The company has also built a broad digital ecosystem around its hardware through tools such as My Intuitive, SimNow, and Case Insights, which help with surgeon training, performance monitoring, workflow efficiency, and predictive maintenance. This makes the systems even more deeply integrated into hospital operations. Intuitive Surgical’s competitive moat is primarily built on its first-mover advantage, high switching costs, integrated ecosystem, and global scale advantages.  First, it has a major first-mover advantage, with decades of clinical use and tens of thousands of peer-reviewed studies supporting the outcomes of procedures performed with the da Vinci system. This long clinical history makes hospitals far less willing to switch to newer competitors that do not have the same level of evidence. Second, switching costs are extremely high because surgeons spend a significant amount of time learning the da Vinci platform, and hospitals often build entire surgical programs, workflows, and staff training around it. Replacing the system would require substantial retraining, workflow changes, and downtime, which creates a strong barrier to competition. Third, Intuitive has built a complete ecosystem rather than simply selling a machine. The combination of systems, recurring instruments, digital tools, service support, analytics, and surgeon education creates a platform that becomes more valuable the longer a hospital uses it. Finally, the company benefits from scale advantages in manufacturing, research and development, and global distribution that make it difficult for competitors to catch up quickly. Together, these advantages create a wide and durable moat that should allow Intuitive Surgical to remain the dominant player in robotic-assisted surgery for many years.

Management

Dave Rosa serves as the CEO of Intuitive Surgical, a role he assumed in 2025 after previously serving as President of the company. He brings nearly three decades of experience at Intuitive Surgical and is one of the leaders most closely associated with the company’s development since its early days. His appointment reflects Intuitive Surgical’s strategic emphasis on continuity, innovation, and long-term execution, as Dave Rosa has been deeply involved in the company’s journey from an early-stage robotics pioneer to the global leader in robotic-assisted surgery. Before becoming CEO, Dave Rosa served as President, where he played a central role in shaping the company’s global strategy, product roadmap, and long-term growth initiatives. Prior to that, he held several senior leadership positions across engineering, product development, clinical affairs, regulatory functions, and commercial operations. This broad experience gives him a deep understanding of every part of Intuitive Surgical’s business model, from the technical development of its systems to the commercial relationships with hospitals and surgeons. Dave Rosa joined Intuitive Surgical in 1996 as the company’s ninth employee and began his career there as a mechanical engineer working on the early generations of the da Vinci system. This is a particularly important aspect of his background, as few CEOs can say they helped build the original core product that later became the foundation of a global platform business. Over the years, Dave Rosa has played an important role in the development and commercialization of major innovations, including newer da Vinci platforms and the expansion into diagnostic solutions such as Ion. His long tenure within the company has given him strong credibility both internally and among customers. Dave Rosa holds a degree in mechanical engineering and has built a reputation as a highly operational, product-focused, and long-term oriented leader. His leadership style appears deeply rooted in understanding customer needs, particularly the challenges faced by surgeons, care teams, and hospitals. This customer-first mindset aligns closely with Intuitive Surgical’s broader focus on improving patient outcomes, lowering the total cost of care, and expanding access to minimally invasive treatment. Since becoming CEO, Dave Rosa has continued to focus on strengthening Intuitive Surgical’s long-term competitive position through continued innovation, platform expansion, and deeper integration of digital tools and training solutions. Under his leadership, the company continues to invest heavily in new product launches, surgeon education, international expansion, and workflow analytics that further strengthen its ecosystem. Given his nearly thirty-year history with the company and his direct involvement in building many of its core technologies, Dave Rosa appears exceptionally well suited to guide Intuitive Surgical through its next phase of growth.

The Numbers

The first number we will look into is the return on invested capital, also known as ROIC. We want to see a 10-year history, with all numbers exceeding 10% in each year.  clearly meets that standard. Intuitive Surgical has historically generated consistently high ROIC, which is a strong sign of a high quality business with a durable competitive moat. The main reason ROIC has remained high for so many years is the strength of its business model. First, the company benefits from a razor and blade structure, where the initial placement of a da Vinci system is followed by recurring revenue from instruments, accessories, and service contracts every time a procedure is performed. This recurring revenue is typically high margin and requires relatively limited incremental capital compared to the earnings it generates, which strongly supports ROIC. Second, Intuitive Surgical benefits from a large installed base and very high switching costs. Once a hospital has invested in the system and trained its surgeons and care teams, additional procedures can be performed without the need for significant new capital investment, which means incremental returns on the existing capital base remain very attractive. Third, the company’s moat in clinical evidence, surgeon training, and workflow integration supports strong pricing power and utilization rates, both of which help maintain profitability. Another important reason ROIC has historically been high is that software, analytics, training, and digital tools such as My Intuitive and SimNow deepen the value of the installed base without requiring capital at the same pace as revenue growth. This creates operating leverage as the ecosystem expands. The reason ROIC has not yet returned to the levels seen in 2018 is likely not a sign of deterioration in the underlying business, but rather a reflection of a larger capital base and elevated investment levels. The decline in 2020 to 10.2% was likely influenced by the pandemic, when elective procedures were delayed and hospital utilization dropped, while the company continued investing for long term growth. Since then, the steady rise from 12,2% in 2022 to 12,6% in 2023, 13,7% in 2024, and 14,9% in 2025 is a very encouraging trend and suggests improving utilization, higher procedure volumes, and stronger contribution from newer systems and digital services. In my view, it is reasonable to expect ROIC to continue improving over time, although perhaps not back to the near 20% level seen in 2018 in the near term. The key drivers remain in place: growing procedure volumes, recurring high margin revenue, a dominant installed base, and expanding international adoption. At the same time, continued investments in research and development, manufacturing capacity, digital capabilities, and new platforms such as Ion and newer da Vinci generations will increase the capital base, which may cap how quickly ROIC expands. I would expect ROIC to trend gradually higher from here as long as procedure growth remains strong, but probably in a more measured way rather than a sharp return to previous peak levels. The most important takeaway is that ROIC has remained consistently above 10% throughout the entire decade, which strongly supports the view that Intuitive Surgical is a high quality compounder with a durable moat.

The next numbers are the book value + dividend. In my old format this was known as the equity growth rate. It was the most important of the four growth rates I used to use in my analyses, which is why I will continue to use it moving forward. As you are used to see the numbers in percentage, I have decided to share both the numbers and the percentage growth year over year. To put it simply, equity is the part of the company that belongs to its shareholders – like the portion of a house you truly own after paying off part of the mortgage. Growing equity over time means the company is becoming more valuable for its owners. So, when we track book value plus dividends, we’re essentially looking at how much value is being built for shareholders year after year. Intuitive Surgical’s equity has increased in most years, and this is primarily driven by the company’s consistently strong profitability and disciplined reinvestment strategy. One of the main reasons equity has grown is that the company generates strong net income and retains a large share of its earnings rather than distributing them through dividends. These retained earnings accumulate on the balance sheet and naturally increase equity over time. Another important reason is that Intuitive Surgical has historically not relied on meaningful debt, which means growth in assets has largely been funded through internally generated profits rather than borrowing. This creates a very healthy balance sheet structure and supports long term growth in shareholder value. The company’s business model also plays an important role. Because the recurring revenue from instruments, accessories, and service contracts generates strong cash flows, Intuitive Surgical is able to continue investing in research and development, new product launches, and international expansion while still building equity. Years where equity growth may have slowed are often linked to temporary fluctuations in profitability, higher investment levels, or share based compensation, rather than weakness in the underlying business. Importantly, the fact that equity has grown in most years is a positive sign and reflects the strength of the company’s earnings power and balance sheet discipline. Looking ahead, this is a trend that is generally expected to continue. As long as Intuitive Surgical continues to grow procedure volumes, expand its installed base, and maintain strong margins, retained earnings should continue to build equity over time. Continued investments in innovation and expansion may create some year to year variation, but the long term direction should remain upward.

Finally, we will analyze the free cash flow. Free cash flow, in short, refers to the cash that a company generates after covering its operating expenses and capital expenditures. I use levered free cash flow margin because I believe that margins provide a better understanding of the numbers. Free cash flow yield refers to the amount of free cash flow per share that a company is expected to generate in relation to its market value per share.  Intuitive Surgical has historically generated strong free cash flow and attractive free cash flow margins, which is exactly what you would expect from a high quality business with strong profitability and relatively moderate investment needs. One of the main reasons free cash flow has been high over the past decade is the company’s business model. The initial sale or lease of a da Vinci system is followed by recurring revenue from instruments, accessories, and service contracts every time a procedure is performed. This recurring revenue is typically high margin and converts well into cash because the additional spending needed to support more procedures is relatively limited. Another important driver is that Intuitive Surgical’s business, while highly advanced technologically, does not require extremely large ongoing investments compared to many industrial companies. A large share of its value comes from its installed base, software, training ecosystem, clinical evidence, and digital tools rather than from constantly building large physical facilities. This allows a significant part of operating profit to turn into free cash flow. The company’s consistently high ROIC also supports strong cash generation, as it is able to generate substantial earnings from each dollar invested in the business. The record free cash flow of $2,5 billion in 2025 is particularly encouraging and was driven by both higher profitability and lower capital expenditures, as management highlighted in the earnings call. This suggests that the company benefited from stronger procedure volumes, better efficiency, and a period where earlier investments are now starting to translate into higher cash generation. The free cash flow margin rising back to 24,7% in 2025, the highest level in the period shown, strongly supports this view. I do think this is a trend that can continue over the long term, although probably not in a perfectly straight line. As procedure volumes continue to grow, especially internationally and with newer platforms such as da Vinci 5 and Ion, recurring revenue should continue to expand. This should support continued strong free cash flow generation. That said, free cash flow can still fluctuate from year to year depending on the timing of larger investments, inventory levels, and the timing of customer payments and supplier payments. Years with major investments in manufacturing capacity, new platforms, or international expansion may temporarily reduce free cash flow even if the underlying business remains strong. Intuitive Surgical primarily uses its free cash flow in two ways. First, it reinvests in the business through research and development, product innovation, manufacturing expansion, digital tools, and surgeon training, all of which help strengthen its competitive moat. Second, it returns capital to shareholders through share repurchases. In 2025, the company repurchased $2.3 billion of stock, which shows that management is using a large portion of excess cash to reduce the share count and create value for shareholders. While the free cash flow yield has been higher in some previous years, it still suggests that the shares are trading at a premium valuation. However, we will revisit valuation later in the analysis.

Debt

Another important aspect to investigate is a company’s debt. We need to determine whether the business carries a manageable amount, specifically whether its long term debt could be repaid within three years based on earnings. This is typically assessed by calculating the long term debt to earnings ratio. In the case of Intuitive Surgical, this calculation is not necessary because the company has no debt. In fact, it has remained debt free for the past twenty years. This is a significant strength and reflects both the quality of the business and its ability to fund growth through internally generated cash rather than relying on borrowing. As a result, debt is unlikely to ever become a concern when evaluating Intuitive Surgical as a long term investment.

Unlock Exclusive Seeking Alpha Discounts – Level Up Your Investing With Zero Risk

If you’ve been thinking about improving your investing process, this is the easiest way to start. These offers are only available through my links, and the Premium plan even comes with a 100% risk-free 7-day trial. Try everything for a week, and if it’s not for you, just cancel. You lose nothing.

1) Seeking Alpha Premium — Try It Free for 7 Days

Access the tools I personally use every day:

• Earnings transcripts

• Stock screeners

• Deep-dive analysis

• Portfolio tracking

• Market news with context that actually matters

Special Price: $269/year (normally $299) + 7-day free trial (for new users only)

Try Premium Free for 7 Days → HERE

(Explore everything — cancel anytime during the trial and pay $0.)

2) Alpha Picks — Proven Stock Ideas

This stock-picking service has delivered +287% returns vs. the S&P 500’s +77% (July 2022–Nov 2025).Great for investors who want curated, long-term picks backed by data.

Special Price: $449/year (normally $499)

Get Alpha Picks → HERE

(Although Alpha Picks doesn’t offer a free trial, its historical outperformance means the subscription can often pay for itself quickly if results persist. For many investors, the potential return far outweighs the upfront cost).

3) Premium + Alpha Picks Bundle — Best Value

Get both services together and save $159.Perfect if you want both broad tools and high-conviction stock ideas.

Special Price: $639/year (normally $798)

Get the Bundle → HERE

(This bundle doesn’t include a free trial, but it gives you both services at a $159 discount. You get Premium’s in-depth research plus Alpha Picks’ high-performing recommendations, making it the most comprehensive option for serious investors.)

Risks

Competition is a risk for Intuitive Surgical because the market for surgical and diagnostic procedures is highly competitive, and hospitals, physicians, and patients may choose alternative treatment options instead of robotic-assisted procedures. While Intuitive Surgical has long held a dominant position in robotic-assisted surgery through its da Vinci platform, it competes not only with other robotic surgery companies but also with established treatment methods such as open surgery, conventional minimally invasive surgery, drug therapies, radiation treatment, and other emerging diagnostic and interventional approaches. Many of these alternatives have a long history of use and are widely accepted in the medical community, which means hospitals and physicians may continue to prefer them in certain situations. One particularly important example is in bariatric procedures, where newer weight loss drugs have already reduced the number of surgeries being performed. As these drugs have become more widely accepted following regulatory approvals, some patients are reconsidering whether surgery is necessary. This can directly reduce procedure volumes for Intuitive Surgical in certain specialties. Over time, advances in drug therapies, radiation treatment, or other non-surgical solutions could make some procedures less dependent on robotic-assisted surgery, which represents a real competitive risk. Competition within robotic-assisted surgery is also becoming increasingly important. Large and well-capitalized companies such as Medtronic and Johnson & Johnson are investing heavily in their own robotic surgery platforms, including Hugo and Ottava. These companies have significant financial resources, broad global sales networks, and long-standing hospital relationships, which makes them credible competitors. In some cases, competing systems may be offered at lower prices than the da Vinci system, which can be attractive to hospitals operating under budget constraints. Competition can affect Intuitive Surgical in several ways. One risk is pricing pressure. If competitors introduce systems or services that are more affordable, hospitals may choose those platforms or use them as leverage in negotiations, which could pressure Intuitive Surgical’s pricing and margins. This is particularly relevant in international markets and in China, where local robotic surgery companies are becoming more aggressive and where pricing in provincial tenders has already become more intense. Domestic players may also be favored in some tenders, which increases the risk of slower growth in an important market. Another risk is that competitors may adopt new technologies more quickly or offer alternative solutions that hospitals perceive as more effective or more cost-efficient. This could slow adoption of Intuitive Surgical’s systems and extend the sales cycle, as hospitals take longer to compare platforms before making a decision. In addition, third-party service providers may emerge with lower-cost maintenance, support, or consulting services for older da Vinci and Ion systems, which could gradually pressure service revenue.

Macroeconomic factors are a risk for Intuitive Surgical because the company depends on hospitals and healthcare systems continuing to invest in expensive surgical equipment and maintain strong procedure volumes. While many surgeries are medically necessary, the purchase of a da Vinci system is a major capital decision rather than an everyday operating expense. When hospitals face pressure from inflation, higher interest rates, budget deficits, or broader economic uncertainty, they may delay purchases of new systems or postpone upgrades to newer platforms such as da Vinci 5. This is especially relevant in international markets where healthcare spending is heavily influenced by government budgets, including Japan, the United Kingdom, and several European countries. In these markets, shifting political priorities or tighter public finances can directly slow capital spending. Economic uncertainty also affects Intuitive Surgical through hospital budgets and financing costs. Many hospitals rely on financing when making large equipment purchases, and higher interest rates increase the cost of borrowing. As a result, hospitals may become more cautious and take longer to approve new system placements. This can extend the sales cycle and make growth in system placements slower and less predictable. Management has already highlighted continued budget challenges in markets such as Japan and the United Kingdom, which shows that this is already affecting demand in certain regions. Macroeconomic factors also influence Intuitive Surgical through rising costs. One important example is tariffs and trade barriers. Management has already guided for an impact of around 1,2% of net revenue from tariffs in 2026. This is particularly important because a significant majority of the company’s instruments and accessories are manufactured in Mexico. Any new tariffs or changes to trade agreements between Mexico and the United States could directly increase production costs and pressure margins. Macroeconomic weakness can also indirectly affect procedure volumes. If patients face higher out of pocket healthcare costs, reduced insurance coverage, or general financial uncertainty, some elective procedures may be postponed. This matters because Intuitive Surgical generates recurring revenue every time a procedure is performed through instruments, accessories, and service contracts. In recent years, Intuitive Surgical has already faced pressures from tariffs, hospital budget constraints, and slower capital spending in some markets. Even though the company’s recurring revenue model provides some stability, these external factors can still affect both revenue growth and margins.

Regulation is a risk for Intuitive Surgical because the company operates in one of the most highly regulated industries in the world. As a medical device company, every product that Intuitive Surgical develops, sells, updates, and services must comply with strict rules from health authorities across the United States and international markets. These regulations cover product design, clinical testing, manufacturing quality, labeling, marketing, data handling, and post market monitoring. If the company fails to meet these requirements, it could face delays, fines, recalls, or restrictions on selling its products. One important regulatory risk is product approvals and upgrades. Intuitive Surgical’s systems, instruments, and digital tools must receive regulatory clearance before they can be sold. In the United States, this includes FDA 510(k) clearance for new devices and, in some cases, additional approvals for major product changes. This means that every significant upgrade to systems such as da Vinci 5, Ion, or new software features may require further regulatory review. If approvals take longer than expected, product launches can be delayed, which can slow growth and reduce the return on research and development investments. Regulation can also affect Intuitive Surgical through product recalls and safety requirements. Because the company’s systems are used in surgeries and diagnostic procedures, any unexpected safety issue, malfunction, or rise in adverse events could lead to warnings, mandatory recalls, or restrictions on product use. A large recall involving da Vinci 5 or Ion would not only create direct costs but could also damage trust among hospitals and surgeons, which may reduce procedure growth. Another important regulatory risk relates to manufacturing and quality standards. Intuitive Surgical must comply with strict quality management requirements, including ongoing inspections of its facilities and processes. If regulators identify weaknesses in manufacturing quality, documentation, or service procedures, the company could face warning letters, production restrictions, or delays in new product approvals. International regulation is another major risk. Intuitive Surgical operates globally, which means it must comply with different regulatory frameworks in markets such as Europe, China, Japan, the United Kingdom, and other international regions. These rules can change over time and are often becoming more complex. For example, European medical device rules have become stricter in recent years, and China’s approval and quota systems can affect how many systems can be sold in the country. Delays in approvals or changes in local requirements can directly affect international growth.

Reasons to invest

Expanding the installed base of its systems is a reason to invest in Intuitive Surgical because it provides a clear and highly scalable path for long term revenue growth while also strengthening the company’s competitive moat. The installed base is at the core of Intuitive Surgical’s business model, as each new da Vinci or Ion system placed in a hospital creates not only an initial sale or lease but also a recurring stream of revenue from instruments, accessories, and service contracts. Every procedure performed on one of these systems requires consumables that need to be replenished, which means each additional system placement supports revenue growth for many years. This creates a highly attractive razor and blade model where system placements today lead to recurring high margin revenue tomorrow. One of the reasons expansion of the installed base is particularly attractive is the strong economics of the business model. Once a system is placed, the ongoing revenue generated from procedures tends to be both recurring and high margin. In 2025, the installed base of da Vinci systems increased by 12% to more than 11.000 systems, while procedure growth increased by approximately 18%. This demonstrates that as the installed base expands, system utilization and recurring revenue also continue to grow. A larger installed base also strengthens Intuitive Surgical’s competitive position. As more hospitals adopt the technology, the systems become increasingly integrated into hospital workflows, surgeon training programs, and operating room routines. Surgeons and care teams spend significant time learning how to use the da Vinci platform, and hospitals often build entire robotic surgery programs around it. This increases switching costs and strengthens customer loyalty, making it less likely that hospitals will move to competing platforms. Another important reason this is attractive is the opportunity for upgrades and newer platforms. Existing customers already familiar with the da Vinci ecosystem are more likely to upgrade to systems such as da Vinci 5 rather than switch to another provider. Management has already highlighted strong demand for upgrades and dual-console systems, particularly in the United States. This creates an additional layer of growth, as the installed base not only expands through new customers but also through upgrades from the existing customer base. International expansion further increases the opportunity. Intuitive Surgical continues to highlight that it is still in the early stages of adoption in markets such as Europe, Japan, and other regions outside the United States. The company continues to invest in expanding access internationally, and management believes there is still a large long term opportunity given the millions of soft tissue procedures that could potentially shift toward minimally invasive robotic surgery.

Innovation is another reason to invest in Intuitive Surgical because it provides a clear and scalable path for long term growth while also strengthening the company’s competitive position. Innovation sits at the center of Intuitive Surgical’s business model, as the company continuously improves its platforms, expands into new procedures, and develops digital tools that make its systems more valuable over time. Rather than relying only on selling more systems, Intuitive creates additional growth by increasing what each system can do, which supports higher utilization, broader adoption, and stronger recurring revenue. One of the reasons innovation is particularly attractive for Intuitive Surgical is that it expands the total addressable market. Every time the company receives approval for new procedures or launches new capabilities, it opens the door to additional surgeries that can be performed on the da Vinci platform. For example, the recent clearance for several cardiac procedures on da Vinci 5 is important because cardiac surgery represents a large and still underpenetrated market. Management has indicated that this alone could represent an opportunity of roughly 160.000 procedures annually in currently approved markets. Similarly, new clearances in procedures such as nipple-sparing mastectomy, hernia repair, appendectomy, and gallbladder removal broaden the clinical use cases and increase demand for the platform. Another important reason innovation matters is that it improves the value proposition for hospitals and surgeons already using the systems. Features such as Force Feedback, enhanced imaging, software upgrades, and better user interfaces help improve surgeon precision, efficiency, and outcomes. This often leads to higher system utilization, which means more procedures per installed system. Management has already highlighted that da Vinci 5 is showing higher utilization than the previous Xi platform, which is exactly what makes innovation so powerful in this business model. It increases the economic value of the existing installed base while supporting future placements. Innovation also strengthens the ecosystem around the platform. Intuitive is not only innovating on hardware but also on digital services and data-driven tools. The My Intuitive+ subscription package includes simulation, telecollaboration, and case insights, allowing surgeons to train, collaborate, and improve performance using real-world data. This creates another layer of recurring revenue while making the platform more embedded in hospital workflows and surgeon education.

Industry tailwinds is a reason to invest in Intuitive Surgical because the broader healthcare industry is moving in a direction that strongly supports long term adoption of robotic-assisted and minimally invasive surgery. These trends are not short term in nature but are driven by structural changes in demographics, hospital economics, surgical practice, and patient expectations. As the market leader in robotic surgery, Intuitive Surgical is exceptionally well positioned to benefit from these long term tailwinds. One of the most important industry tailwinds is the global shift toward minimally invasive surgery. Hospitals, surgeons, and patients increasingly prefer procedures that reduce trauma to the body compared with traditional open surgery. Minimally invasive approaches typically lead to smaller incisions, lower complication rates, shorter recovery times, and faster discharge from the hospital. Robotic-assisted surgery fits directly into this trend because it often improves precision and control compared with conventional laparoscopy. This is particularly important because management still believes the company is in the early stages of adoption, with millions of soft tissue procedures still performed using open surgery or traditional minimally invasive techniques. Another major tailwind is the aging global population. As populations grow older, the number of procedures for cancer, hernias, gynecology, urology, and other conditions is expected to rise over time. Older populations naturally require more surgical interventions, which increases the total addressable market for Intuitive Surgical’s systems. This demographic trend should support procedure growth for many years. Healthcare systems are also increasingly focused on efficiency and reducing total treatment costs, which supports adoption of robotic-assisted surgery. Studies continue to show that robotic procedures can lead to shorter hospital stays, fewer complications, and lower readmission rates. For example, some recent analyses have shown significantly shorter length of stay and lower readmission rates compared with laparoscopic surgery in procedures such as hernia repair. Even if the robotic equipment itself is expensive, the lower total cost of care can make the economics attractive for hospitals and payers. A particularly important tailwind is the ongoing shift of surgeries into outpatient settings and ambulatory surgery centers. More procedures are moving away from traditional hospitals into lower-cost care settings, and minimally invasive surgery is helping enable this shift. Intuitive has specifically highlighted ambulatory surgery centers as a multiyear growth opportunity, supported by refurbished Xi systems and tailored economic offerings. This expands the company’s addressable market beyond traditional hospital systems and creates another avenue for system placements and procedure growth. Clinical evidence is another major tailwind. Over time, more peer-reviewed studies continue to demonstrate the clinical and economic benefits of robotic-assisted surgery. This growing body of evidence makes hospitals more comfortable allocating capital toward robotic systems. It also strengthens the case for wider adoption among surgeons and payers. As the evidence base expands, it supports a virtuous cycle of greater trust, higher adoption, and further procedure growth.

Support the Blog

I want to keep the blog free and accessible for everyone. If you enjoy the content and would like to support it, you can buy me a cup of coffee through PayPal. Every little bit helps and is truly appreciated!

Valuation

Now it is time to calculate the share price. I perform three different calculations that I learned at a Phil Town seminar. If you want to make the calculations yourself for this or other stocks, you can do so through the tools page on my website, where you have access to all three calculators for free.

The first is called the Margin of Safety price, which is calculated based on earnings per share (EPS), estimated future EPS growth, and estimated future price-to-earnings ratio (P/E). The minimum acceptable rate of return is 15%. I chose to use an EPS of 7,87, which is from the year 2025. I have selected a projected future EPS growth rate of 15%. Finbox expects EPS to grow by 16,6% in the next five years, but 15% is the highest I use. Additionally, I have selected a projected future P/E ratio of 30, which is double the growth rate. This decision is based on Intuitive Surgical's historically higher price-to-earnings (P/E) ratio. Finally, our minimum acceptable rate of return has already been established at 15%. After performing the calculations, we determined the sticker price (also known as fair value or intrinsic value) to be $236,10. We want to have a margin of safety of 50%, so we will divide it by 2. This means that we want to buy Intuitive Surgical at a price of $118,05 (or lower, obviously) if we use the Margin of Safety price.

The second calculation is known as the Ten Cap price. The rate of return that a company owner (or stockholder) receives on the purchase price of the company essentially represents its return on investment. The minimum annual return should be at least 10%, which I calculate as follows: The operating cash flow last year was 3.030, and capital expenditures were 540. I attempted to analyze their annual report to calculate the percentage of capital expenditures allocated to maintenance. I couldn't find it, but as a rule of thumb, you can expect that 70% of the capital expenditures will be allocated to maintenance purposes. This means that we will use 378 in our calculations. The tax provision was 435. We have 354,5 outstanding shares. Hence, the calculation will be as follows: (3.030 – 378 + 435) / 354,5 x 10 = $87,08 in Ten Cap price.

The final calculation is referred to as the Payback Time price. It is a calculation based on the free cash flow per share. With Intuitive Surgical's free cash flow per share at $7,03 and a growth rate of 15%, if you want to recoup your investment in 8 years, the Payback Time price is $110,97.

Conclusion

I believe that Intuitive Surgical is an intriguing company led by strong management. The company has built its moat through its first mover advantage, high switching costs, integrated ecosystem, and global scale advantages. It has consistently achieved high ROIC, which is a trend that I expect to continue given the strength of its business model and recurring revenue streams. Intuitive Surgical also delivered its highest free cash flow ever in 2025, and free cash flow is expected to continue growing as procedure volumes increase and the installed base expands. Competition is a risk for Intuitive Surgical because the company not only faces growing competition from large medical technology players such as Medtronic and Johnson & Johnson, but also from alternative treatment methods such as traditional surgery, laparoscopy, drug therapies, and radiation. If hospitals and physicians choose lower cost robotic systems or non surgical treatments, it could pressure Intuitive Surgical’s procedure growth, pricing power, and margins. Macroeconomic factors are a risk for Intuitive Surgical because hospitals may delay purchasing or upgrading expensive surgical systems when faced with inflation, higher interest rates, budget pressure, or government spending constraints. In addition, tariffs and rising production costs can pressure margins, while weaker economic conditions may also reduce elective procedure volumes and slow recurring revenue growth. Regulation is a risk for Intuitive Surgical because its systems, software, and instruments must meet strict approval, safety, and manufacturing standards across multiple countries, and any delays or failures can slow product launches and international growth. In addition, safety issues or regulatory findings could lead to recalls, fines, or sales restrictions that would pressure both revenue growth and customer trust. Expanding the installed base of its systems is a reason to invest in Intuitive Surgical because every new da Vinci or Ion placement creates a long term stream of high margin recurring revenue from instruments, accessories, and service contracts. At the same time, a larger installed base strengthens switching costs, supports future upgrades such as da Vinci 5, and deepens Intuitive Surgical’s competitive moat through greater integration into hospital workflows and surgeon training. Innovation is another reason to invest in Intuitive Surgical because it expands the number of procedures that can be performed on its platforms while making each installed system more valuable over time. By continuously improving hardware, software, imaging, and digital tools, Intuitive drives higher utilization, stronger recurring revenue, and a wider competitive moat. Industry tailwinds are also a reason to invest in Intuitive Surgical because long term trends such as the shift toward minimally invasive surgery, an aging population, and growing demand for more cost efficient care all support continued growth in robotic assisted procedures. As the market leader, Intuitive Surgical is well positioned to benefit as adoption expands across hospitals, outpatient centers, and international markets. Overall, I believe that Intuitive Surgical is a great company, and buying shares at $236, which represents the intrinsic value based on the Margin of Safety price, would be a good long term investment.

My personal goal with investing is financial freedom. It also means that to obtain that, I do different things to build my wealth. If you have some extra hours to spare each month, you can turn a few hours a week into a substantial amount of money in a few years. If you are interested to know how to do it, you can read this post.

I hope you enjoyed my analysis! While I can’t post about every company I analyze, you can stay updated on my trades by following me on Twitter. I share real-time updates whenever I buy or sell, so if you’re making your own investment decisions, be sure to follow along!

Some of the greatest investors in the world believe in karma, and to receive, you will have to give. If you appreciated my analysis and want to get some good karma and show your appreciation, I would kindly ask you to donate a bit to Rolda. It is an organization that helps the animals in Ukraine. Animals are the forgotten souls in a war, and they need all the help they can get. If you have a few bucks to spare, it doesn't matter how little, I will kindly ask you to donate a bit here. Thank you.